Vectus Biosystems Limited (VBS.AX)
Vectus Biosystems Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Rosebery, NSW, AU. The stock last traded at $0.16, up 0.00% on the session, giving a market capitalisation of $9.9M. Its beta of 0.29 implies it has historically moved less than the broad market.
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Vectus Biosystems Limited is most often compared with the following Healthcare names: